---
schema_version: "secwatch.filing_event.v1"
accession: "0001564590-22-011090"
form_type: "8-K"
ticker: "TXMD"
cik: "0000025743"
company_name: "TherapeuticsMD, Inc."
filed_at: "2022-03-18T23:59:59+00:00"
generated_at: "2026-06-26T21:48:40.931413+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# TherapeuticsMD receives Nasdaq delisting notice for bid price non-compliance; CFO resigns

## Summary
- Received Nasdaq delisting notice on March 15, 2022 for failing to maintain $1.00 minimum bid price within 180-day compliance period.
- Company requested a hearing to appeal; trading stay pending Panel decision.
- Intends to consider reverse stock split to regain compliance with minimum bid price requirement.
- CFO James C. D'Arecca resigns effective April 1, 2022; Michael C. Donegan appointed Interim CFO.
- Search for permanent CFO initiated.

## SEC filing metadata
- accession: 0001564590-22-011090
- form_type: 8-K
- ticker: TXMD
- cik: 0000025743
- company_name: TherapeuticsMD, Inc.
- filed_at: 2022-03-18T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 3.01, 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/25743/000156459022011090/0001564590-22-011090-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/25743/000156459022011090/txmd-8k_20220314.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001564590-22-011090
- JSON: https://secwatch.observer/filing/0001564590-22-011090.json
- Plain text: https://secwatch.observer/filing/0001564590-22-011090.txt

## Key facts
- Executive change
  James C. D’Arecca resigned as Chief Financial Officer at TherapeuticsMD, Inc..
  - Action: resigned
  - Role: Chief Financial Officer
  source text: On March 14, 2022, Mr. James C. D’Arecca, the Chief Financial Officer and Principal Financial Officer of the Company, notified the Company of his decision to resign from such positions, effective as of April 1, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/25743/000156459022011090/0001564590-22-011090-index.htm
- Executive change
  Michael C. Donegan was appointed as Interim Chief Financial Officer at TherapeuticsMD, Inc..
  - Action: appointed
  - Role: Interim Chief Financial Officer
  source text: Mr. Michael C. Donegan, the Vice President – Finance and Chief Accounting Officer of the Company, will succeed Mr. D’Arecca as Interim Chief Financial Officer and Principal Financial and Accounting Officer as of the effective date of Mr. D’Arecca’s resignation.
  evidence_url: https://www.sec.gov/Archives/edgar/data/25743/000156459022011090/0001564590-22-011090-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.